Nevertheless, some studies reported that breast cancer patients display increased serum SDF-1 levels, in particular patients with HER2-overexpressing breast tumors [40] and that serum SDF-1 concentration has prognostic value [19, 40–44]. This evidence concerns the gene ERBB2 and breast carcinoma.